Warm nasal cells mount stronger defenses against cold-causing coronaviruses and rhinoviruses than those exposed to cooler temperatures, an in vitro experiment finds.
A clinical trial finds that the anticoagulant apixaban, which has been prescribed to help COVID-19 patients recover, is ineffective and in rare instances dangerous.
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
Launched with a $172 million philanthropic donation and funds from the state of Victoria, the Melbourne-based research institute aims to construct drug discovery platforms to speed the introduction of new therapies.
The 81-year-old director says that he will step back from his positions this December, but that he will continue working to advance science and public health.
Evidence thus far shows that pregnant people infected with SARS-CoV-2 are at higher risk for severe disease and death, as well as complications in their pregnancies.
Alejandra Manjarrez, PhD | Feb 18, 2022 | 9 min read
Evidence suggests that COVID-19 is primarily an airborne disease. Yet the details of how transmission occurs are still debated and frequently misunderstood.
Scientists linked hamsters in a Hong Kong pet shop to 50 cases of the Delta variant in what appears to be the second documented occurrence of animals infecting people with SARS-CoV-2.
Madhvi Menon will discuss immune profiling of COVID-19 patients and Jyoti Phatak-Sheldon will highlight the use of RNAscope in situ hybridization in SARS-CoV-2 research.
Only half of volunteers deliberately exposed to SARS-CoV-2 developed an infection. None developed serious symptoms, paving the way for further challenge trials.